Author:
Antoniou Tony,Pajer Kathleen,Gardner William,Penner Melanie,Lunsky Yona,McCormack Daniel,Tadrous Mina,Mamdani Muhammad,Gozdyra Peter,Juurlink David N.,Gomes Tara
Abstract
AbstractThe COVID-19 pandemic was associated with increases in the prevalence of depression and anxiety among children and young adults. We studied whether the pandemic was associated with changes in prescription benzodiazepine use. We conducted a population-based study of benzodiazepine dispensing to children and young adults ≤ 24 years old between January 1, 2013, and June 30, 2022. We used structural break analyses to identify the pandemic month(s) when changes in prescription benzodiazepine dispensing occurred, and interrupted time series models to quantify changes in dispensing following the structural break and compare observed and expected benzodiazepine use. A structural break occurs where there is a sudden change in the trend of a time series. We observed an immediate decline in benzodiazepine dispensing of 23.6 per 100,000 (95% confidence interval [CI]: -33.6 to -21.2) associated with a structural break in April 2020, followed by a monthly decrease in the trend of 0.3 per 100,000 (95% CI: -0.74 to 0.14). Lower than expected benzodiazepine dispensing rates were observed each month of the pandemic from April 2020 onward, with relative percent differences ranging from − 7.4% (95% CI: -10.1% to – 4.7%) to -20.9% (95% CI: -23.2% to -18.6%). Results were generally similar in analyses stratified by sex, age, neighbourhood income quintile, and urban versus rural residence. Further research is required to understand the clinical implications of these findings and whether these trends were sustained with further follow-up.
Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Racine N, McArthur BA, Cooke JE, Eirich R, Zhu J, Madigan S (2021) Global prevalence of depressive and anxiety symptoms in children and adolescents during COVID-19: a Meta-analysis. JAMA Pediatr 175:1142–1150
2. Chavira DA, Ponting C, Ramos G (2022) The impact of COVID-19 on child and adolescent mental health and treatment considerations. Behav Res Ther 157:104169
3. Tiger M, Wesselhoeft R, Karlsson P et al (2023) Utilization of antidepressants, anxiolytics, and hypnotics during the COVID-19 pandemic in Scandinavia. J Affect Disord 323:292–298
4. Campbell TJ, Men S, Shearer D et al (2023) The epidemiology of benzodiazepine-related toxicity in Ontario, Canada: a population-based descriptive study. Can J Public Health 15:1–11
5. Canadian Institute for Health Information (2024) Canadian COVID-19 Intervention Timeline — Data Tables. https://www.cihi.ca/en/canadian-covid-19-intervention-timeline. Accessed April 15